NCT02623868

Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability to CKD-519 new formulation in healthy male subjects.

Detailed description

Open-label, Randomized, 3-period, 6-sequence, crossover study

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	CKD-519 50mg 2Tabs.	after taking Standard meal, CKD-519 50mg 2Tabs. administration.
DRUG	CKD-519 100mg 1Tab.	after taking Standard meal, CKD-519 100mg 1Tab. administration.
DRUG	CKD-519 100mg 1Cap.	after taking Standard meal, CKD-519 100mg 1Cap. administration.

Timeline

• Start date: 2015-10-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2015-12-08
• Last updated: 2016-01-20

Locations

1 site across 1 country: South Korea